BC 11 hydrobromide
Cat. No. 4372
Chemical Name: Carbamimidothioic acid (4-boronophenyl)methyl ester hydrobromide
Biological ActivitySelective urokinase (uPA) inhibitor (IC50 = 8.2 μM). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation. Also decreases viability of MDA-MB231 breast cancer cells in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Longo et al (2015) Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells Molecules 20 9879. PMID: 26029857.
Smith et al (2011) Elucidating novel urokinase-type plasminogen activator inhibitors. Int.Soc.Thromb.Haemost. (Abstract) 9 819.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for BC 11 hydrobromide include:
Semina et al (2016) Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur.J.Cell Biol.. PMID: 27324124.
Do you know of a great paper that uses BC 11 hydrobromide from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BC 11 hydrobromide, supplier, BC11, HBr, urokinase, inhibitor, inhibits, uPA, urokinase-type, plasminogen-activator, inhibitors, Tocris Bioscience, Urokinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailableRitonavir
HIV-1 and HIV-2 protease inhibitorAcetyl Pepstatin
High affinity aspartic protease inhibitor; inhibits HIV-1/2 proteinasesONO 6818
High affinity and selective human neutrophil elastase 1 (HNE1) inhibitor; orally active
December 3 - 7, 2016
San Francisco, CA,